Please assess the completion status of the following clinical trial:

Trial Title: Ketamine as a Rapid Treatment for Post-traumatic Stress Disorder (PTSD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men or women, 21-55 years of age;~* Participants must have a level of understanding sufficient to agree to all tests and examinations required by the protocol and must sign a written informed consent document;~* Participants must fulfill DSM-IV criteria for current civilian or combat-related PTSD, based on clinical assessment by a study psychiatrist and on the CAPS (score must be at least 50 at screening and prior to each infusion - this is done to ensure at least moderate severity and to safeguard against high placebo response rates); additionally, clinicians will use clinical judgment to assess if patients are symptomatic enough to receive each infusion~* Women must be using a medically accepted reliable means of contraception (if using an oral contraceptive medication, they must also be using a barrier contraceptive) or not be of childbearing potential (i.e., surgically sterile, postmenopausal for at least one year);~* Women of childbearing potential must have a negative pregnancy test at screening and pre-infusion;~* Participants must be able to identify a family member, physician, or friend (i.e. someone who knows them well) who will participate in a Treatment Contract (and e.g. contact the study physician on their behalf in case manic symptoms or suicidal thoughts develop).~Exclusion Criteria:~* Women who plan to become pregnant, are pregnant or are breast-feeding (because the medical risk of using ketamine during pregnancy and breast-feeding is unknown);~* Serious, unstable medical illnesses such as hepatic, renal, gastroenterologic, respiratory, cardiovascular, endocrinologic, neurologic, immunologic, or hematologic disease (including gastro-esophageal reflux disease, obstructive sleep apnea, history of difficulty with airway management during previous anesthetics, ischemic heart disease and uncontrolled hypertension, and history of severe head injury);~* Clinically significant abnormal findings of laboratory parameters, physical examination, or ECG;~* Patients with uncorrected hypothyroidism or hyperthyroidism;~* Hormonal treatment (e.g., estrogen) started in the 3 months prior to the first infusion day;~* Use of evidence-based individual psychotherapy (such as prolonged exposure) and other non-pharmacological treatments during the study;~* Histories of autism, mental retardation, pervasive developmental disorders, or Tourette's syndrome;~* History of one or more seizures without a clear and resolved etiology;~* History of (hypo)mania;~* Past or current presence of psychotic symptoms, or diagnosis of a lifetime psychotic disorder including schizophrenia or schizoaffective disorder;~* Drug or alcohol abuse or dependence within the preceding 3 months (given that this might otherwise contribute to their symptoms, however, a rather narrow time period was chosen such as to allow participation by individuals with a history of substance abuse or dependence problems that could be secondary to their PTSD, and to more closely approximate patients seen in real-world settings);~* Previous recreational use of ketamine or PCP;~* Current diagnosis of bulimia nervosa or anorexia nervosa;~* Diagnosis of schizotypal or antisocial personality disorder (since these are known to reduce the possibility of study completion; other Axis II diagnoses will be allowed);~* Patients judged clinically to be at serious and imminent suicidal or homicidal risk.~* A blood pressure of one reading over 160/90 or two separate readings over 140/90 at screen or baseline visits.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- Ketamine (Type: EXPERIMENTAL): Single dose 0.5 mg/kg IV (in the vein) infused over 40 minutes
- Midazolam (Type: ACTIVE_COMPARATOR): single dose 0.045 mg/kg IV infused over 40 minutes

Based on this trial design, predict the completion outcome and termination type (if applicable).